© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 81283 pertains to the gene analysis of the interferon, lambda 3 (IFNL3) gene, specifically focusing on the identification of the rs12979860 variant. The IFNL3 gene is crucial as it encodes a cytokine that is part of the Type 1 interferons and the interleukin-10 (IL-10) family, which includes IL28A and IL29. This gene is located on the long (q) arm of chromosome 19 at position 13, where it exists in a cluster with other related genes. The expression of the IFNL3 gene can be stimulated by viral infections, indicating its role in the immune response. The rs12979860 single nucleotide polymorphism (SNP) variant is particularly significant as it has been linked to susceptibility to Hepatitis C Virus (HCV) and influences the body's ability to spontaneously clear the infection. Additionally, this variant affects the response of infected individuals to antiviral drug treatments. The blood sample required for this analysis is obtained through a separate procedure, and the testing methods may include amplified refractory mutation system-polymerase chain reaction (ARMS-PCR) or polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), both of which are advanced techniques used to detect specific genetic variants.
© Copyright 2025 Coding Ahead. All rights reserved.
The gene analysis for the rs12979860 variant of the interferon, lambda 3 (IFNL3) gene is indicated for the following conditions:
The procedure for conducting the gene analysis for the rs12979860 variant involves several key steps:
Post-procedure care primarily involves the management of the patient’s expectations regarding the results of the genetic analysis. Patients may be advised on the implications of the findings, particularly in relation to their susceptibility to Hepatitis C Virus and the potential effectiveness of antiviral treatments. Follow-up consultations may be necessary to discuss the results and any subsequent steps in their care plan, including further testing or treatment options based on the genetic findings.
| Short Descr | IFNL3 GENE | Medium Descr | IFNL3 GENE ANALYSIS RS12979860 VARIANT | Long Descr | IFNL3 (interferon, lambda 3) (eg, drug response), gene analysis, rs12979860 variant | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Service Paid under Fee Schedule or Payment System other than OPPS | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | GA | Waiver of liability statement issued as required by payer policy, individual case | GW | Service not related to the hospice patient's terminal condition | XU | Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2018-01-01 | Added | Code Added. |
Get instant expert-level medical coding assistance.